ZELTIA NEWS PharmaMar’s Aplidin® Phase 3 ADMYRE Trial in Relapsed Refractory Multiple Myeloma Achieves Initial Target Response Rate and the IDMC recommends continuation of the study until completion
• Stage 1 of Phase 3 study completed • Stage 2 of Phase 3 study will enrol additional 190 patients Madrid, 18th December: The Independent Data Monitoring Committee (IDMC)
has notified PharmaMar, a biopharmaceutical subsidiary of Grupo Zeltia (ZEL.MC),
that it recommends completion of the on-going Phase 3 trial of Aplidin® (ADMYRE)
in patients with relapsed/refractory multiple myeloma. The two-stage, 2:1
randomized Phase 3 study is evaluating Aplidin® in combination with
dexamethasone versus dexamethasone alone. The IDMC recommendation follows a
comprehensive analysis of efficacy and safety data from the 60 patients required in
the first stage of the Phase 3 trial in which the study comfortably met the
PharmaMar will enroll an additional 190 patients in the second stage of the Phase 3
trial. The number of centers initially planned will be doubled in order to accelerate
the recruitment process. The Primary endpoint of the phase 3 study is a 60%
improvement in progression free survival. Enrollment of Stage 2 of this phase 3 is
About Aplidin®
Aplidin® is an antitumour agent of marine origin, originally isolated from the marine tunicate
Aplidiumalbicans, and currently obtained by chemical synthesis. Aplidin® is PharmaMar's second most
advanced compound. It is currently in phase II clinical trials for solid and haematological malignant
neoplasias like T cell lymphoma and in phase III clinical trials for multiple myeloma. Aplidin® has been
designated an orphan drug by the European Commission (EC) and the FDA for multiple myeloma (MM).
About PharmaMar
PharmaMar is a biopharmaceutical subsidiary of Grupo Zeltia; it is a world leader in discovering,
developing and selling marine-based drugs to treat cancer. Yondelis® is Spain's first antitumour drug. It
is currently approved for soft tissue sarcoma (STS) in 39 countries outside the EEA, and for platinum-
sensitive relapsed ovarian cancer (ROC) in 25 of those countries plus Brazil. Yondelis® is approved for
STS and platinum-sensitive ROC in all 30 countries of the EEA. Yondelis® is also undergoing Phase II
trials on breast and paediatric cancers. PharmaMar has four other compounds in clinical development:
Aplidin®, Zalypsis®, PM01183 and PM060184. PharmaMar also has a rich pipeline of pre-clinical
candidates and a major R&D programme
About Zeltia
Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-
based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of
the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer
care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech
firm focused on discovering and developing new drugs against Alzheimer’s disease and other
neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular
diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing
(RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that
are leaders in their respective market segments.
Important note
PharmaMar, which is headquartered in Madrid (Spain), is a subsidiary of Zeltia, S.A. (Spanish stock
exchange: ZEL), which has been listed on the Spanish Stock Exchange since 1963 and on Spain's
Electronic Market since 1998. This document is a press release, not a prospectus. This document does
not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or
subscribe shares of the company. Moreover, no reliance should be placed upon this document for any
investment decision or contract and it does not constitute a recommendation of any type with regard to
For more information +34 91 444 4500
This note is also available on the PharmaMar web site:www.pharmamar.com and atZeltia's website: www.zeltia.com
Reproductive Services Ovulation Timing and Breeding Management Ovulation Timing. The most common cause of infertility in the bitch is inappropriately timed breeding. Litter size and pregnancy rate is maximized if the bitch is bred within her most fertile window, which is 2-6 days after ovulation. In many bitches, sexual receptivity (“flagging” for the male and standing
T09 ADMINISTRACIÓN LOCAL ENTIDADES NECESARIAS; Municipios, la provincia y las islas. ENTIDADES POTESTATIVAS; Submunicipales -pedanías, caseríos-, Comarcas, Áreas Metropolitanas y Mancomunidades. MUNICIPIO: Ente público d carácter local,, objeto; defender intereses locales. Entidad básica de la Org. Territorial del Estado. Tiene personalidad jurídica, se rige por la LBRL, tienen su pr
ZELTIA NEWS 
About PharmaMar